Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Dupilumab gets early access nod from UK regulator for atopic dermatitis

severe atopic dermatitis

Source: Alamy 

New monoclonal antibody approved for severe atopic dermatitis by the UK Medicines and Healthcare products Regulatory Agency

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a positive opinion for dupilumab in atopic dermatitis under the Early Access to Medicines Scheme (EAMS). 

The decision means that eligible patients will now be able to receive the treatment despite it not yet having a marketing authorisation in the European Union. 

Dupilumab is a monoclonal antibody targeting the interleukin-4 receptor alpha, which plays a pivotal role in the signalling pathways that lead to chronic skin inflammation in atopic dermatitis. 

In clinical trials involving more than 1,500 patients with moderate-to-severe atopic dermatitis, patients saw a reduction in the extent and severity of atopic dermatitis lesions, as well as reductions in itch. There were also improvements in quality-of-life measures and sleep, which is often affected by the disease. 

Patients receiving dupilumab were more likely to develop conjunctivitis and injection-site reactions compared with those who received placebo in the clinical trials. The MHRA noted that as dupilumab is a targeted therapy it is not associated with the same risks as general immunosuppression, but that the long term risks are unknown. 

To access treatment via the early access scheme, eligible patients must have severe atopic dermatitis and have failed to respond to, be intolerant to or be ineligible for other therapies. Although the treatment is being investigated in children in clinical trials, the EAMS approval applies only to adults. 

“Severe atopic eczema is a disease that has a major impact on quality of life and the treatment options available are limited and can have harmful effects,” states the MHRA in its report. “Under EAMS, dupilumab is being made available to those patients with the highest need who have run out of treatment options.” 

Dupilumab was developed as part of an antibody collaboration between Regeneron and Sanofi that has been going since 2007. An application for marketing authorisation was filed with the European Medicines Agency in December 2016 and is currently under review.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202469

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £55.00Buy now
  • Pharmacy and the US Health Care System

    Pharmacy and the US Health Care System

    A complete source of current information about the US health care system. Includes concise reports on trends, regulations, policy and finances.

    £48.00Buy now
  • FASTtrack: Chemistry of Drugs

    FASTtrack: Chemistry of Drugs

    An accessible introduction to the key aspects of organic chemistry, elementary medicinal chemistry, and biochemistry.

    £24.00Buy now
  • Essentials of Pharmacy Management

    Essentials of Pharmacy Management

    Essentials of Pharmacy Management is an accessible introduction to management. It provides a jump-start to leadership roles and career advancement.

    £42.00Buy now
  • Nuclear Pharmacy

    Nuclear Pharmacy

    An accessible introduction to concepts and applications in nuclear pharmacy.

    £32.00Buy now
  • Zoonoses


    An accessible textbook covering zoonotic diseases, which affect humans but are contracted from animals.

    £47.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • severe atopic dermatitis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.